{"schema_version":"secwatch.filing_event.v1","accession":"0001214659-24-005635","form_type":"8-K","ticker":"ALZN","cik":"0001677077","company_name":"Alzamend Neuro, Inc.","filed_at":"2024-03-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.080700+00:00","generated_at":"2026-06-04T05:25:15.791716+00:00","sec_items":["1.01","3.01","3.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Alzamend Neuro faces Nasdaq delisting over MVLS; sells $780K Series B convertible to affiliate","bullets":["Nasdaq notified ALZN it fails MVLS rule; delisting scheduled for April 4 unless appeal stays it.","Company will appeal to Hearings Panel by April 2; Common Stock continues trading pending decision.","Sold Series B convertible preferred stock and warrants for $780K to Ault Lending (affiliate); aggregate purchases now $2M of $6M available.","Unregistered sale under Section 4(a)(2) exemption."],"urls":{"canonical":"https://secwatch.observer/filing/0001214659-24-005635","json":"https://secwatch.observer/filing/0001214659-24-005635.json","markdown":"https://secwatch.observer/filing/0001214659-24-005635.md","text":"https://secwatch.observer/filing/0001214659-24-005635.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1677077/000121465924005635/0001214659-24-005635-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1677077/000121465924005635/p3292438k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T05:25:15.791716+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c5e4de1b8dec4a08a7709fd25993bb739e9bff05","claim":"Alzamend Neuro, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).","evidence_excerpt":"iled with the Securities and Exchange Commission (the “ SEC ”), which will remove the Common Stock from listing and registration on Nasdaq. The Company will request an appeal of the Staff’s determination to a Hearings Panel (the “ Panel ”), pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series, which is required to be submitted electronically no later than April 2, 2024. The hearing request will stay the suspension of the Common Stock and the filing of the Form 25-NSE pending the Panel’s decision, and the Common Stock will continue to trade on the Nasdaq Capital Market un","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1677077/000121465924005635/0001214659-24-005635-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"market value"},{"label":"Rules","value":"5550(b)(2)"}],"fact_type":"exchange_compliance_notice"},{"claim_id":"a1b60f313dd907667e4b4e83b66649ea333ce4eb","claim":"Alzamend Neuro, Inc. entered into Agreement with Ault Lending, LLC valued at purchase price of $2.0 million (effective 2024-01-31).","evidence_excerpt":"On March 26, 2024, Alzamend Neuro, Inc., a Delaware corporation (the “ Company ”), pursuant to the Securities Purchase Agreement (the “ Agreement ”) entered into with Ault Lending, LLC, a California limited liability company (the “ Purchaser ”) on January 31, 2024","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1677077/000121465924005635/0001214659-24-005635-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Ault Lending, LLC"},{"label":"Value","value":"purchase price of $2.0 million"},{"label":"Effective","value":"2024-01-31"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}